Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Pierce

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
British Journal of Cancer|December 31, 2021
The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activityCarolyn J Edwards, Angelica Sette, Carl Cox, et al.
Cancers|August 7, 2021
Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase InhibitionJeffrey R Whiteaker, Tao Wang, Lei Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
British Journal of Cancer|December 31, 2021
The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activityCarolyn J Edwards, Angelica Sette, Carl Cox, et al.
Cancers|August 7, 2021
Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase InhibitionJeffrey R Whiteaker, Tao Wang, Lei Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 5